Plain-English translation of NCT06579404 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a fully automated insulin delivery system called CamAPS HX, which uses a smartphone app, an insulin pump, and a glucose sensor that work together to automatically adjust your insulin doses throughout the day and night. The system is being compared to standard insulin therapy with a glucose sensor to see if it helps people with type 2 diabetes control their blood sugar better over 26 weeks at home.
Many people with type 2 diabetes struggle to manage their insulin therapy because it requires frequent manual adjustments and careful monitoring. This trial is investigating whether an automated system that continuously adjusts insulin doses could take the burden off patients and achieve better blood sugar control with fewer low blood sugar episodes.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to use either the fully automated insulin pump system or standard insulin therapy with a glucose sensor, both for 26 weeks in your home. You'll wear a small glucose sensor on your body and, if assigned to the automated system, use a smartphone app that controls your insulin pump automatically. Throughout the study, you'll visit the clinic for check-ups, wear the devices continuously, and may answer questions about how the system affects your daily life and emotional well-being.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Australia
Austria
Czechia
France
Switzerland